Home
Browse
Create
Search
Log in
Sign up
Upgrade to remove ads
Only $2.99/month
Toxicities for therapies in Melanoma
STUDY
Flashcards
Learn
Write
Spell
Test
PLAY
Match
Gravity
Terms in this set (18)
Nivolumab
better efficacy and toxicity compared to ipilimumab
Preferred immunotherapy for adjuvant therapy of stage 3 completely resected disease
Ipilimumab
targets CTLA-4 on cytotoxic T cells
approved first line in unresectable and metastatic melanoma
increased disease free period and overall five year survival
Toxicities grade 3 or higher by over 40% of patients, 50% of patients had to discontinue due to toxicity
Ipilimumab Toxicites
can happen during treatment or several weeks after treatment is completed
2-3 weeks skin: rash, pruritus, vitiligo,
6-7 weeks Gi and liver: diarrhea, colitis, elevated enzymes, elevated bilirubin, hepatitis
>9 weeks Endocrine: hypophysitis, hypothyroidism
Ipilimumab toxicity management
Grade 1 and 2: symptom control continue therapy
Grade 3 and 4: hold therapy and treat with high dose steroids
Interferon Alfa
response rates are low 10-30%, but half of those who do respond have long disease free survival and potentially cure
high dose therapy improves survival for stage 2B/C with primary lesion >4mm or involving regional lymph nodes rendered disease free by surgery
Interferon Alfa Toxicities
fever
flu-like
severe fatigue
depression, suicidal ideation
hepatic toxicity
hematologic toxicity
no one finishes course of therapy
Dosed 5 times a day for 4 weeks
Dabrafenib/Trametinib
Indicated for completely resected stage 3 disease with BRAFV600 mutation and SLN metastasis ?1mm with BRAFV600 mutation
Toxicity: fevers, fatigue, nausea
T-VEC
Talimogene laherparepvec
genetically modified herpes simplex virus injected into lesion
Indicated for unresectable cutaneous, subcutaneous, and nodular lesions in patients with recurrent melanoma after initial surgery
T-VEC
Talimogene laherparepvec Toxicities
-Most resolved with 72 hours
-vasculitis, fatigue, chills, HA, cellulitis, NVD, bacterial infection, herpes virus infection, pain/inflammation at injection site, myalgia, arthralgia, flu-like, fever
Vemurafenib Toxicities
BRAFV600 mutation tested
works good for 6 months, then recurrence
Common: peripheral edema, fatigue, HA, rash/skin disorders, photosensitivity, NVD, arthralgia
Rare: QTc prolongation
Unique: development of squamous cell carcinoma
Dabrafenib Toxicities
BRAFV600 mutation tested
can be used as single agent or in combo with trametinib- always used in combo
combo better than vemurafenib alone
combo suppress downstream BRAF therapy resistance
HA, hyperkeratosis, hyperglycemia, hand foot syndrome, arthralgia, alopecia, squamous cell carcinoma
Trametinib Toxicities
-inhibits MEK activation, combo with BRAF mutation targeted therapy
-not for patients who have received previous BRAF inhibitor therapy
skin rash, diarrhea, anemia, increased LFT, hemorrhage, HTN, cardiomyopathy
decreased squamous cell carcinoma when combined with Dabrafenib
Cobimetinib Toxicities
Combo with vemurafenib
indicated in treatment of unresectable or metastatic melanoma in patients with BRAFV600 mutation
decreased ejection fraction, photosensitivity, decreased electrolytes, diarrhea, myelosuppresion, increased LFT, visual impairment, increased SCr
slight increase in toxicities with combo but decrease in squamous cell carcinoma
Pembrolizumab
binds PDL1
indicated in unresectable or metastatic melanoma
less toxicity and better DFS and OS than ipilimumab, 1st line in metastatic before ipilimumab
nivolumab/ipilimumab combo
indicated in untreated, unresectable stage 3 or metastatic stage 4 melanoma
adverse effects: fatigue, NVD, pruritus, rash, fever, decreased appetite, increased LFT, colitis, hypothyroidism
Chemo
single or combo rarely cures any metastatic disease
Interleukin 2
stimulates cytotoxic T cells
life-threatening capillary leak syndrome: hypotension, visceral edema, dyspnea, tachycardia, arrhythmias, acute renal failure
pt receive therapy in ICU
Dacarbazine (DTIC)
approved for use in metastatic melanoma, only chemo approved in melanoma
THIS SET IS OFTEN IN FOLDERS WITH...
Virus host interactions
18 terms
Fluid Balance
22 terms
Endocrine Patho
19 terms
YOU MIGHT ALSO LIKE...
Multiple Myeloma
91 terms
Thyroid Disorders
88 terms
Peptic Ulcer Disease
30 terms
Pathophysiology And Disease
37 terms
OTHER SETS BY THIS CREATOR
Musculoskeletal - Certification Exam- Winland-Brow…
105 terms
MSK exam
92 terms
Professional Practice
77 terms
Men's Health
163 terms